<![CDATA[Genomic Prostate Score Identifies Biologically Low-Risk Disease]]>

Data ReadoutpositiveGenomic Prostate ScorePositive

AI Analysis

Summary

Genomic Prostate Score (GPS) demonstrated the ability to identify biologically low-risk prostate cancer, with clinically higher-risk patients showing favorable GPS results achieving superior 6-year event-free survival rates across treatment arms.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Patients with clinically higher-risk disease but favorable GPS results demonstrated higher 6-year event-free survival rates across treatment arms compared to those at lower clinical risk

Importance:4/10

Sentiment:

0.60

prostate cancergenomic testingrisk stratificationevent-free survivalclinical outcomes

Read the original article

Published by Cancer Network on July 2, 2026 4:00 PM

Read Original